Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation-Reference-Cited by-同舟云学术

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

Published:2018-03 Issue:3 Volume:18 Page:225-234
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chan Henry^ORCID,Phillips Madeline,Maganti Manjula,Farooki Sophia,Piza Rodriguez Giovanni,Masih-Khan Esther,Chen Christine,Prica Anca,Reece Donna,Tiedemann Rodger,Trudel Suzanne,Kukreti Vishal

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference52 articles.

1. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial;Boyd;Leukemia,2012

2. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group;Palumbo;J Clin Oncol,2015

3. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project;Avet-Loiseau;Leukemia,2013

4. Multiple myeloma: evolving genetic events and host interactions;Kuehl;Nat Rev Cancer,2002

5. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant;Chang;Br J Haematol,2004

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular genetic aberrations in the pathogenesis of multiple myeloma;Asian Biomedicine;2023-08-01

2. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions;Blood Cancer Journal;2022-05-30

3. Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk;Annals of Hematology;2022-05-18

4. Diagnosis and Management of Multiple Myeloma;JAMA;2022-02-01

5. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams;Frontiers in Oncology;2022-01-20